Genetic Polymorphisms in Genes Involved in Inflammation and Prostate Cancer Risk

2008 ◽  
Author(s):  
Claudia A. Salinas
2005 ◽  
Vol 173 (4S) ◽  
pp. 71-71
Author(s):  
Peter E. Clark ◽  
M. Craig Hall ◽  
Kristin L. Lockett ◽  
Jianfeng Xu ◽  
Sigun L. Zheng ◽  
...  

2019 ◽  
Vol 40 (1) ◽  
pp. 27-34
Author(s):  
MUNEER ABBAS ◽  
TSHELA MASON ◽  
ALIZA IBAD ◽  
MOZNA KHRAIWESH ◽  
VICTOR APPREY ◽  
...  

2010 ◽  
Vol 34 (3) ◽  
pp. 345-349 ◽  
Author(s):  
Anastasios Karatzas ◽  
Eirini Giannatou ◽  
Vassilios Tzortzis ◽  
Stavros Gravas ◽  
Evangellos Aravantinos ◽  
...  

PLoS ONE ◽  
2014 ◽  
Vol 9 (5) ◽  
pp. e94683 ◽  
Author(s):  
Marcelo Chen ◽  
Yi-Ling Huang ◽  
Yu-Chuen Huang ◽  
Irene M. Shui ◽  
Edward Giovannucci ◽  
...  

2003 ◽  
Vol 89 (4) ◽  
pp. 691-696 ◽  
Author(s):  
H Nakazato ◽  
K Suzuki ◽  
H Matsui ◽  
N Ohtake ◽  
S Nakata ◽  
...  

2002 ◽  
Vol 12 (3) ◽  
pp. 182-196 ◽  
Author(s):  
Steven S Coughlin ◽  
Ingrid J Hall

Tumor Biology ◽  
2019 ◽  
Vol 41 (3) ◽  
pp. 101042831983083 ◽  
Author(s):  
Hasnain Imtiaz ◽  
Sharmin Afroz ◽  
Md Amir Hossain ◽  
Sm Faysal Bellah ◽  
Md Mostafizur Rahman ◽  
...  

The polymorphisms of invasion suppressor gene CDH1 and DNA mismatch repair gene Exo1 have been reported to play critical role in the development, tumorigenesis, and progression of several kinds of cancers including prostate cancer. This study was designed to analyze the contribution of single-nucleotide polymorphisms of the CDH1 (-160C/A) and Exo1 (K589E) to prostate cancer susceptibility in Bangladeshi population. The study included 100 prostate cancer cases and age-matched 100 healthy controls. Polymerase chain reaction-restriction fragment length polymorphism analysis was used to determine the genetic polymorphisms. A significant association was found between CDH1 -160C/A (rs16260) and Exo1 (rs1047840, K589E) polymorphisms and prostate cancer risk. In case of CDH1 -160C/A polymorphism, the frequencies of the three genotypes C/C,C/A, and A/A were 45%, 48%, and 7% in cases and 63%, 32%, and 5% in controls, respectively. The heterozygote C/A genotype and combined C/A + A/A genotypes showed 2.10-fold (odds ratio = 2.1000, 95% confidence interval = 1.2956–4.0905, p = 0.013) and 2.08-fold (odds ratio = 2.0811, 95% confidence interval = 1.1820–3.6641, p = 0.011) increased risk of prostate cancer, respectively, when compared with homozygous C/C genotypes. The variant A allele also was associated with increased risk of prostate cancer (odds ratio = 1.6901, 95% confidence interval = 1.0740–2.6597, p = 0.0233). In case of Exo1 (K589E) polymorphism, G/A heterozygote, A/A homozygote, and combined G/A + A/A genotypes were found to be associated with 2.30-, 4.85-, and 3.04-fold higher risk of prostate cancer, respectively (odds ratio = 2.3021, 95% confidence interval = 2.956–4.0905, p = 0.0031; odds ratio = 4.8462, 95% confidence interval = 1.0198–23.0284, p = 0.0291; OR = 3.0362, 95% confidence interval = 1.7054–5.4053, p = 0.0001, respectively). The “A” allele showed significant association with increased susceptibility (2.29-fold) to prostate cancer (odds ratio = 2.2955, 95% confidence interval = 1.4529–3.6270, p = 0.0004). Our results suggest that CDH1 -160C/A and Exo1 K589E polymorphisms are associated with increased susceptibility to prostate cancer in Bangladeshi population.


Sign in / Sign up

Export Citation Format

Share Document